Orlistat

Tirzepatide and semaglutide confer greater weight loss than other FDA-approved obesity medications with no significantly higher risk for adverse events, according to findings from a network meta-analysis published in Obesity.

Obesity medications were prescribed to very few Military Health System beneficiaries between October 2017 and September 2022, according to a study published in Obesity.

Most adults with obesity were not prescribed an obesity medication from 2015 to 2023, and of those prescribed an agent, 55% had at least one prescription fill, according to study data published in Diabetes, Obesity and Metabolism.

The risk for all-cause mortality decreases among patients with knee or hip osteoarthritis who achieve slow-to-moderate, but not fast, weight loss via anti-obesity medications, according to data published in Arthritis & Rheumatology.

During the past 2 decades, Endocrine Today has reported on the latest developments in treating obesity. For its 20th year, the publication is taking a look back.

LAS VEGAS – Obesity was an independent risk factor for the development of colorectal cancer among patients who underwent weight loss surgery or who were on weight loss medication, according to a presentation.

Pharmacotherapy can be an important intervention for adolescents with obesity, according to a speaker at the Obesity Medicine Association fall conference.

Discussing weight gain and prescribing weight loss therapies or interventions for people with a BMI of 25 kg/m2 or greater could help reduce mortality risk and slow the progression of obesity, according to a speaker.

A modified-release fixed-dose formulation of orlistat and acarbose is well tolerated and may be an effective approach for weight loss, according to results of a phase 2a pilot study published in Obesity Science and Practice.